Day: April 26, 2024

HONG KONG, April 26, 2024 (GLOBE NEWSWIRE) — SOLOWIN HOLDINGS (Nasdaq: SWIN) (“SOLOWIN” or the “Company”), a securities brokerage company that offers comprehensive financial services primarily to Chinese investors, today announced that the Company, through its subsidiary, Solomon JFZ (Asia) Holdings Limited (“Solomon”), strengthened the partnership with OSL Digital Securities (“OSL”), the digital asset platform of OSL Group (863.HK) – Hong Kong’s only publicly listed company fully dedicated to digital assets, to facilitate the in-kind subscription and redemption processes essential for the successful deployment and management of Hong Kong’s first spot virtual asset exchange-traded funds (“ETFs”). Solomon is the first batch of SFC-approved participating dealer of this innovative in-kind subscription and redemption...

The following decisions were taken at the Ordinary General Meeting of Shareholders of Vilkyskiu pienine AB which was held on the 26 April 2024: Item 1 of the Agenda: Regarding Company’s Consolidated annual report for 2023. Heard. Item 2 of the Agenda: Regarding independent auditor‘s conclusion on the Company’s consolidated and separated financial Statements for 2023. Heard. Item 3 of the Agenda: Regarding comments and proposals of Company’s Supervisory Board. Comments and proposals heard. Item 4 of the Agenda: Regarding the approval of Company’s separated and consolidated financial statement for the year 2023. Resolution: Company’s separated and consolidated financial statements for the year 2023 has been approved. Item 5 of the Agenda: Regarding the approval of the remuneration report of the Company for 2023,...

Uponor Corporation, Stock Exchange Release, April 26, 2024, 4.15 p.m. EET The arbitral tribunal has confirmed GF’s redemption right over the minority shares in Uponor and trading in Uponor’s shares has been suspended The arbitral tribunal appointed by the Redemption Committee of the Finland Chamber of Commerce in connection with the redemption proceedings concerning the minority shares in Uponor Corporation (“Uponor”) has in its interim award confirmed that Georg Fischer AG (“GF”) has the right to redeem the minority shares in Uponor and that GF has the right to obtain title to the minority shares by posting a security approved by the arbitral tribunal for the payment of the redemption price and the possible interest accruing thereon. Uponor announced on March 22, 2024, that Uponor has resolved to apply for the termination of public trading...

The Ordinary General Meeting of Shareholders of ŽEMAITIJOS PIENAS, AB (hereinafter – the Company), which took place on 26 April 2024, heard the auditors’ report, as well as consolidated annual report for 2023 and other documents submitted to the Meeting of Shareholders and made decisions on relevant issues. Decisions and other documents are attached to this notice. Arnas MatuzasHead of Legal E-mail: a.matuzas@zpienas.lt Attachmentsabzemaitijospienas-2023-12-31-enIndependent auditors report_ŽP-2023 ENG FDecisions of OGMS

VERO BEACH, FL, April 26, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Mitesco, Inc. (OTC:MITI, “the Company”, www.mitescoinc.com ) today announced that it has added two (2) additional professionals to its recently formed “Advisory Board”. The Board is comprised of individuals with specific subject matter expertise who may assist the Company in finding and evaluating qualified companies and businesses for integration into the public holding company. The Advisory Board is a non-executive board, and its participants shall not be subject to any of the regulations under Section 16 of the Securities Act. The latest appointments to the Advisory Board who provide infrastructure, GIS, outsourcing and data center operations experience are as follows: Tom Simon is the owner of Synthos, LLC, [ www.Synthos.co ], a provider of development and...

The Annual General Meeting of Telia Lietuva, AB (hereinafter ‘the Company’ or ‘Telia Lietuva’) shareholders was held on 26 April 2024. The Annual General Meeting of Telia Lietuva decided: – To approve the audited annual financial statements of the Company for the year 2023. The annual report of the Company for the year 2023, prepared by the Company, assessed by the auditors and approved by the Board, was presented to the shareholders. – To allocate the Company’s profit for the year 2023: from the Company’s distributable profit of EUR 170,974 thousand to allocate EUR 52,435 thousand for the payment of dividends for the year 2023, i.e. EUR 0.09 dividend per share, and carry forward to the next financial year an amount of EUR 118,539 thousand as retained earnings (undistributed profit). To allocate EUR 37 thousand for tantiemes...

STOCK EXCHANGE RELEASE 26 April 2024, at 4.00 p.m. EEST Decisions of the Organisational Meeting of Harvia Plc’s Board of Directors Heiner Olbrich was elected the Chair and Catharina Stackelberg-Hammarén was elected the Vice Chair of the Board of Directors at the Board of Directors’ organisational meeting that took place today after Harvia Plc’s Annual General Meeting. Board of Directors elected from among its members Hille Korhonen (Chair), Anders Holmén and Markus Lengauer as members of the Audit Committee. In addition, Harvia Plc’s Board of Directors decided to establish a Personnel and Remuneration Committee. The Committee’s task is to assist the Board of Directors in issues related to personnel and remuneration. The Board of Directors elected from among its members Heiner Olbrich (Chair), Olli Liitola and Catharina Stackelberg-Hammarén...

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and PersistenceSOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, announced that it has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of ALLO-316, an AlloCAR T™ investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell...